The Park­er In­sti­tute aims to speed up can­cer R&D, carv­ing out du­pli­cate IRBs at top cen­ters

The Park­er In­sti­tute for Can­cer Im­munother­a­py has brought its 6 top cen­ters to­geth­er to sup­port a sim­ple ini­tia­tive de­signed to shave months off the clin­i­cal tri­al process. In­stead of each field­ing their own IRB — in­sti­tu­tion­al re­view board — they’ve agreed to des­ig­nate one that will work for the en­tire net­work for mul­ti-cen­ter stud­ies.

IRBs are tasked with keep­ing a sharp eye on tri­als to pre­serve pa­tient safe­ty, over­see over­all con­duct and main­tain da­ta in­tegri­ty. But they can al­so slow down the work, par­tic­u­lar­ly when each of these groups field their own re­view boards for each study. A col­lec­tive agree­ment to des­ig­nate one IRB as the re­view board of record could save a con­sid­er­able amount of time, these sci­en­tists agreed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.